Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can new criteria better spot a spine disease that mimics back pain?

NCT ID NCT07724847

Recruiting now Knowledge-focused Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study aims to validate the 2025 ASAS-SPARTAN classification criteria for axial spondyloarthritis (axSpA) in Chinese patients with chronic back pain. AxSpA is a chronic inflammatory spine disease often misdiagnosed. Researchers will compare the new criteria against standard clinical diagnosis to see if they improve accuracy and reduce over-diagnosis in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If the new criteria prove accurate, they could help doctors diagnose axial spondyloarthritis earlier and reduce over-diagnosis in Chinese patients.
What could go wrong
This is an observational validation study, not a treatment trial. The criteria may not perform as well in this population as hoped, and results may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS (AXSPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis Spondylarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AXIAL SPONDYLOARTHRITIS (AXSPA) CHRONIC BACK PAIN SPONDYLOARTHRITIS (SPA)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.